Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Jul 27
- 3 min read
Updated: Jul 28
27/07/2026
Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline (Ref)
Argenx announced that the companies had entered into a definitive agreement under which argenx would acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.
The acquisition would adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, with potential across multiple autoimmune diseases.
FB102 demonstrated positive Phase 1b data in vitiligo, while Phase 2 data in celiac disease are expected in H2 2026.
The transaction would strengthens argenx's immunology portfolio by expanding its pipeline with a differentiated mechanism targeting pathogenic T-cell and NK-cell activity via CD122 biology.
AbelZeta received FDA clearance for registrational Phase 2 trial of C-CAR168 in Refractory Lupus Nephritis (Ref)
AbelZeta Pharma announced that the Company received the US FDA clearance under its Regenerative Medicine Advanced Therapy designation for the multiple-center registrational Phase 2 trial for C-CAR168 (anti-CD20/BCMA bispecific CAR-T), for the treatment of patients with Lupus Nephritis (LN) refractory to standard therapy.
The Phase 2 trial was designed to further evaluate the safety and efficacy of C-CAR168 in this patient population.
AbelZeta was also actively evaluating the potential of C-CAR168 in other major disease indications.
InnoCare's fadeucravacitinib met it primary endpoint in Phase 3 Psoriasis study (Ref)
InnoCare Pharma announced that its fadeucravacitinib (ICP-488; TYK2 inhibitor) met the primary endpoint in the registrational Phase 3 study in patients with moderate-to-severe plaque psoriasis.
The Phase 3 study demonstrated that fadeucravacitinib achieved the primary endpoint with statistical significance and clinically meaningful improvement. In addition, multiple secondary endpoints were successfully met, demonstrating a consistent treatment effect across efficacy measures.
Fadeucravacitinib also showed a favorable safety profile, which was consistent with previous clinical studies, and no new safety signals were identified.
Detailed efficacy and safety data from the study will be presented at upcoming international scientific congresses and/or published in a peer-reviewed academic journal.
Jacobio dosed the first patient in China in Phase 2a trial of JAB-8263 for Rheumatoid arthritis (Ref)
Jacobio Pharma announced that its independently developed JAB-8263 (BET inhibitor) had completed the dosing of the first patient in a Phase 2a trial for rheumatoid arthritis (RA) in China.
This milestone marked JAB-8263’s expansion from oncology into autoimmune diseases. It was also the first clinical trial globally to evaluate a BET inhibitor for the treatment of RA.
The Phase 2a clinical trial was designed to primarily evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of JAB-8263 in patients with RA.
Bambusa Therapeutics reported preliminary Proof-of-concept data for BTT001 in Atopic Dermatitis (Ref)
Bambusa Therapeutics announced preliminary clinical proof-of-concept data for BBT001 (anti- IL-4Rα and IL-31) in bio-naïve patients with moderate-to-severe atopic dermatitis (AD).
BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time.
Fast-onset and potent itch relief was observed as early as Day 1 after the first dose alongside robust and durable suppression of Type 2 inflammatory biomarkers.
Favorable safety, extended half-life and low immunogenicity findings supported BBT001’s potential best-in-disease profile and infrequent maintenance dosing.
Additional topline data from ongoing BBT001 studies in atopic dermatitis and chronic spontaneous urticaria expected in 1H 2027.
